These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 28324123

  • 1. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR, Maslowski K.
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [Abstract] [Full Text] [Related]

  • 2. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH.
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [Abstract] [Full Text] [Related]

  • 3. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Jul; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 4. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
    Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M.
    J Bone Miner Metab; 2008 Jul; 26(6):635-41. PubMed ID: 18979164
    [Abstract] [Full Text] [Related]

  • 5. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.
    Clin Exp Rheumatol; 2007 Jul; 25(3):464-6. PubMed ID: 17631747
    [Abstract] [Full Text] [Related]

  • 6. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D, Gennari L, Martini G, Valleggi F, De Paola V, Avanzati A, Nuti R.
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [Abstract] [Full Text] [Related]

  • 7. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM.
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
    Muschitz C, Feichtinger X, Haschka J, Kocijan R.
    Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
    [Abstract] [Full Text] [Related]

  • 9. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid for Paget's disease of bone.
    Maricic M.
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [Abstract] [Full Text] [Related]

  • 11. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 12. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K.
    Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
    [Abstract] [Full Text] [Related]

  • 13. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM, Scott LJ.
    Drugs; 2007 May; 67(5):793-804. PubMed ID: 17385948
    [Abstract] [Full Text] [Related]

  • 14. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 15. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 16. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
    Ang G, Feiglin D, Moses AM.
    Endocr Pract; 2003 Jul; 9(4):280-3. PubMed ID: 14561571
    [Abstract] [Full Text] [Related]

  • 17. Pharmacotherapy of Paget's disease of bone.
    Reid IR.
    Expert Opin Pharmacother; 2012 Apr; 13(5):637-46. PubMed ID: 22339140
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone.
    Reid IR, Wattie D, Gamble GD, Kalluru R, Cundy T.
    Calcif Tissue Int; 2017 Mar; 100(3):250-254. PubMed ID: 27866237
    [Abstract] [Full Text] [Related]

  • 19. The use of zoledronic acid for Paget's disease of bone.
    Maricic M.
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muñoz-Gomez J, Ballesta AM.
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.